[ad_1]
This “EPRO, electronic patient diary and eCOA market forecast in 2028-COVID-19 impact and global analysis by solution type, EPRO, ClinRO, ObsRO, PerfO and electronic patient diary); model); end users, hospitals, academic institutions, Pharmaceutical companies, etc.) and geography” Report has been added to ResearchAndMarkets.com provide.
In 2020, the market value of ePRO, electronic patient diary and eCOA is USD 1.34292 billion and is expected to reach USD 4.13035 billion by 2028; it is expected to grow at a compound annual growth rate of 15.08% during 2020-2028.
Increasing demand for electronic health records (EHR) and increased use of smartphones are driving market growth. However, concerns about data privacy hindered the growth of the ePRO, electronic patient diary and eCOA markets.
The use of electronic clinical outcome assessment (eCOA) promotes adaptation to the “new normal” because it is a method of collecting patient data electronically using technologies such as smart home devices, handheld displays, wearable devices, electronic diaries, and tablets A web server to allow trial stakeholders (patients, healthy volunteers, researchers, and nursing staff) to report results directly and digitally.
Although historically COA was only related to the evaluation of patient-related outcomes (PRO), the FDA has now expanded the definition to include PerfO, ClinRO, and ObsRO along with PRO. Simply put, when the above parameters are reported electronically, they conform to the eCOA spectrum.
The eCOA/ePRO platform has substantial benefits…
The full story on Benzinga.com
[ad_2]
Source link
